Nature Communications,
Год журнала:
2024,
Номер
15(1)
Опубликована: Янв. 29, 2024
Abstract
The
constant
emergence
of
SARS-CoV-2
variants
continues
to
impair
the
efficacy
existing
neutralizing
antibodies,
especially
XBB.1.5
and
EG.5,
which
showed
exceptional
immune
evasion
properties.
Here,
we
identify
a
highly
conserved
epitope
targeted
by
broad-spectrum
antibody
BA7535,
demonstrates
high
neutralization
potency
against
not
only
previous
variants,
such
as
Alpha,
Beta,
Gamma,
Delta
Omicron
BA.1-BA.5,
but
also
more
recently
emerged
subvariants,
including
BF.7,
CH.1.1,
XBB.1,
XBB.1.5,
XBB.1.9.1,
EG.5.
Structural
analysis
Spike
trimer
with
BA7535-Fab
using
cryo-EM
indicates
that
BA7535
recognizes
cryptic
receptor-binding
domain
(RBD)
epitope,
avoiding
most
mutational
hot
spots
in
RBD.
Furthermore,
structural
simulation
based
on
interaction
BA7535-Fab/RBD
complexes
dissects
broadly
effect
latest
variants.
Therapeutic
prophylactic
treatment
alone
or
combination
BA7208
protected
female
mice
from
circulating
BA.5
XBB.1
variant
infection,
suggesting
serves
potential
target
for
developing
potent
therapeutic
antibodies
vaccines.
Cell,
Год журнала:
2022,
Номер
186(2), С. 279 - 286.e8
Опубликована: Дек. 14, 2022
The
BQ
and
XBB
subvariants
of
SARS-CoV-2
Omicron
are
now
rapidly
expanding,
possibly
due
to
altered
antibody
evasion
properties
deriving
from
their
additional
spike
mutations.
Here,
we
report
that
neutralization
BQ.1,
BQ.1.1,
XBB,
XBB.1
by
sera
vaccinees
infected
persons
was
markedly
impaired,
including
individuals
boosted
with
a
WA1/BA.5
bivalent
mRNA
vaccine.
Titers
against
were
lower
13-
81-fold
66-
155-fold,
respectively,
far
beyond
what
had
been
observed
date.
Monoclonal
antibodies
capable
neutralizing
the
original
variant
largely
inactive
these
new
subvariants,
responsible
individual
mutations
identified.
These
found
have
similar
ACE2-binding
affinities
as
predecessors.
Together,
our
findings
indicate
present
serious
threats
current
COVID-19
vaccines,
render
all
authorized
antibodies,
may
gained
dominance
in
population
because
advantage
evading
antibodies.
Abstract
Continuous
evolution
of
Omicron
has
led
to
a
rapid
and
simultaneous
emergence
numerous
variants
that
display
growth
advantages
over
BA.5
(ref.
1
).
Despite
their
divergent
evolutionary
courses,
mutations
on
receptor-binding
domain
(RBD)
converge
several
hotspots.
The
driving
force
destination
such
sudden
convergent
its
effect
humoral
immunity
remain
unclear.
Here
we
demonstrate
these
can
cause
evasion
neutralizing
antibody
drugs
convalescent
plasma,
including
those
from
breakthrough
infection,
while
maintaining
sufficient
ACE2-binding
capability.
BQ.1.1.10
(BQ.1.1
+
Y144del),
BA.4.6.3,
XBB
CH.1.1
are
the
most
antibody-evasive
strains
tested.
To
delineate
origin
evolution,
determined
escape
mutation
profiles
neutralization
activity
monoclonal
antibodies
isolated
individuals
who
had
BA.2
infections
2,3
.
Owing
immune
imprinting,
especially
infection
reduced
diversity
binding
sites
increased
proportions
non-neutralizing
clones,
which,
in
turn,
focused
pressure
promoted
RBD.
Moreover,
show
RBD
could
be
accurately
inferred
by
deep
mutational
scanning
4,5
,
trends
BA.2.75
subvariants
well
foreseen
through
constructed
pseudovirus
mutants.
These
results
suggest
current
herd
vaccine
boosters
may
not
efficiently
prevent
variants.
The Lancet Infectious Diseases,
Год журнала:
2023,
Номер
24(2), С. e70 - e72
Опубликована: Дек. 15, 2023
The
SARS-CoV-2
saltation
variant
BA.2.86,
which
was
quickly
designated
as
a
under
monitoring
after
its
emergence,
has
garnered
global
attention.
Although
BA.2.86
did
not
show
substantial
humoral
immune
escape
and
growth
advantage
compared
with
current
dominant
variants,
such
EG.5.1
HK.3,
it
showed
remarkably
high
ACE2
binding
affinity.1Yang
S
Yu
Y
Jian
F
et
al.Antigenicity
infectivity
characterisation
of
BA.2.86.Lancet
Infect
Dis.
2023;
23:
e457-e459Summary
Full
Text
PDF
PubMed
Scopus
(36)
Google
Scholar,
2Wannigama
DL
Amarasiri
M
Phattharapornjaroen
P
al.Tracing
the
new
in
community
through
wastewater
surveillance
Bangkok,
Thailand.Lancet
e464-e466Summary
(11)
3Wang
Q
Guo
Liu
L
receptor
affinity
spike.Nature.
(published
online
Oct
23.)https://doi.org/10.1038/s41586-023-06750-wGoogle
4Uriu
K
Ito
J
Kosugi
al.Transmissibility,
infectivity,
evasion
variant.Lancet
e460-e461Summary
(29)
5Sheward
DJ
Yang
Westerberg
al.Sensitivity
to
prevailing
neutralising
antibody
responses.Lancet
e462-e463Summary
(22)
Scholar
This
increased
affinity,
coupled
distinct
antigenicity,
could
enable
accumulate
immune-evasive
mutations
during
low-level
populational
transmission,
akin
previous
evolution
from
BA.2.75
CH.1.1
XBB.6Cao
Song
W
Wang
al.Characterization
enhanced
Omicron
BA.2.75.Cell
Host
Microbe.
2022;
30:
1527-1539Summary
(74)
7Cao
al.Imprinted
immunity
induces
convergent
RBD
domain
evolution.Nature.
614:
521-529PubMed
8Yue
C
al.ACE2
transmissibility
XBB.1.5.Lancet
278-280Summary
(108)
9Wang
Li
Z
al.Evolving
sublineage
SARS-CoV-2.iScience.
26108254
Summary
(3)
With
just
one
additional
mutation
(L455S)
predecessor
JN.1
rapidly
became
predominant
France
(figure
A;
appendix
1
p
12),
surpassing
both
so-called
FLip
(L455F+F456L)
strains.
A
thorough
investigation
into
capability
JN.1,
particularly
given
few
mutations,
is
imperative.FigureJN.1
shows
profound
decreased
affinityShow
full
caption(A)
Sequence
percentages
prevalent
variants
since
August,
2023,
including
BA.2·86
(the
original
subvariants,
except
JN.1),
HV.1,
FLip+A475V,
HK.3.
advantages
relative
HK.3
past
two
months
these
strains
are
denoted
legend
within
parentheses.
Data
collected
covSPECTRUM.
(B)
50%
titer
(NT50)
convalescent
plasma
against
measured
individuals
who
received
three
CoronaVac
doses
had
breakthrough
infection
BA.5
or
BF.7
followed
by
XBB
reinfection
(n=54).
Labels
for
geometric
mean
titers
(GMT)
located
above
each
group,
fold
changes
statistical
significances
indicated
GMT
labels.
Below
dashed
line
labels
specifying
numbers
negative
samples
related
limit
detection
(NT50=20).
Two-tailed
Wilcoxon
signed-rank
tests
paired
were
used.
*p<0·05,
**p<0·01,
***p<0·001,
****p<0·0001.
(C)
human
(angiotensin-converting
enzyme
2)
affinities
(XBB.1.5+L455F+F456L),
HV.1
(XBB.1.5+L452R+F456L),
EG.5
(XBB.1.5+F456L),
JD.1.1
(XBB.1.5+L455F+F456L+A475V),
(BA.2.86+L455S)
determined
surface
plasmon
resonance
sensorgrams.
KD
values
(nM)
displayed
bars,
all
replicates
represented
points.
(D)
Class
Nabs
resistance
pseudovirus
XBB.1.5,
EG.5,
JD.1.1,
IC50
(n=8).
when
D614G
other
labelled.
(μg
per
mL)
approved
candidate
monoclonal
drugs
targeting
spike
assessed
pseudovirus.
IC50=50%
inhibitory
concentration;
KD=equilibrium
dissociation
constant;
NAbs=neutralising
antibodies;
nM=nanomolarView
Large
Image
Figure
ViewerDownload
Hi-res
image
Download
(PPT)
(A)
nM=nanomolar
We
first
study
using
pseudovirus-based
neutralisation
assays
recovering
infection.
These
individuals,
having
inactivated
vaccines,
subsequently
contracted
(XBB
subvariants
S486P
substitution)
infections.
Our
included
cohorts,
27
participants
post-vaccination
infections
another
patients
reinfected
(appendix
2).
significantly
B).
finding
evidenced
2·1-fold
decrease
among
post-BA.5
1·1-fold
NT50
B;
13).
Additionally,
JN.1's
surpassed
that
competitive
(EG.5+L452R)
(FLip+A475V).
also
lower
their
parental
acquiring
L452R
A475V
respectively,
explaining
advantages.
As
L455
on
interface
between
14),10Nutalai
R
Zhou
D
Tuekprakhon
al.Potent
cross-reactive
antibodies
following
vaccinees.Cell.
185
(31.e18):
2116Summary
(76)
L455S
change
JN.1.
By
resonance,
we
found
notable
reduction
domain,
indicating
capabilities
come
at
expense
reduced
C).
carried
(XBB.1.5+FLip+A475V)
resulted
enhancing
(XBB.1.5+FLip).
However,
affect
affinity.
Considering
predominantly
epitope
antibodies,
earlier
research,
our
further
examined
response
eight
XBB.1·5-neutralising
class
antibodies.7Cao
Pseudovirus
addition
ability
evade
D).
effectively
compensated
BA.2.86's
susceptibility
this
group
Similarly,
FLip+A475V
(JD.1.1)
(HK.3),
offering
insights
trend
variants.
In
terms
therapeutic
SA55
retained
efficacy
E).
Together,
findings
suggest
greatly
compensation
weakness
antibodies.
summary,
inheriting
antigenic
diversity
acquisition
L455S,
achieved
extensive
across
1,
2,
3
antibodies,1Yang
higher
resistant
like
JD.1·1,
binding.
evolutionary
pattern,
similar
transition
XBB,2Wannigama
highlights
importance
closely
BA.2.75,
despite
unremarkable
capabilities.
Such
survive
transmit
low
levels
difference
would
allow
them
target
populations
have
potential
highly
cost
publication
been
corrected.
corrected
version
appeared
thelancet.com/infection
January
3,
2024
YC
inventor
provisional
patent
applications
BD
series
includes
BD55–5514
(SA55).
founder
Singlomics
Biopharmaceuticals.
All
authors
declare
no
competing
interests.
.pdf
(3.2
MB)
Help
pdf
files
Supplementary
.xls
(.02
xls
2
Correction
Lancet
Dis
published
Dec
15.
https://doi.org/10.1016/S1473-3099(23)00744-2Yang
S,
Y,
Xu
al.
Fast
heavy
pressure.
https://doi.org/10.1016/S1473-3099(23)00744-2—In
Correspondence,
author's
name
should
printed
Yunlong
Cao.
corresponding
email
address
read
[email
protected].
corrections
made
Jan
2024.
Full-Text
Nature Communications,
Год журнала:
2023,
Номер
14(1)
Опубликована: Май 16, 2023
In
late
2022,
SARS-CoV-2
Omicron
subvariants
have
become
highly
diversified,
and
XBB
is
spreading
rapidly
around
the
world.
Our
phylogenetic
analyses
suggested
that
emerged
through
recombination
of
two
cocirculating
BA.2
lineages,
BJ.1
BM.1.1.1
(a
progeny
BA.2.75),
during
summer
2022.
XBB.1
variant
most
profoundly
resistant
to
BA.2/5
breakthrough
infection
sera
date
more
fusogenic
than
BA.2.75.
The
breakpoint
located
in
receptor-binding
domain
spike,
each
region
recombinant
spike
confers
immune
evasion
increases
fusogenicity.
We
further
provide
structural
basis
for
interaction
between
human
ACE2.
Finally,
intrinsic
pathogenicity
male
hamsters
comparable
or
even
lower
multiscale
investigation
provides
evidence
suggesting
first
observed
increase
its
fitness
rather
substitutions.
Nature Communications,
Год журнала:
2023,
Номер
14(1)
Опубликована: Фев. 14, 2023
Abstract
Convergent
evolution
of
SARS-CoV-2
Omicron
BA.2,
BA.4,
and
BA.5
lineages
has
led
to
the
emergence
several
new
subvariants,
including
BA.2.75.2,
BA.4.6.
BQ.1.1.
The
subvariant
BQ.1.1
became
predominant
in
many
countries
December
2022.
subvariants
carry
an
additional
often
redundant
set
mutations
spike,
likely
responsible
for
increased
transmissibility
immune
evasion.
Here,
we
established
a
viral
amplification
procedure
easily
isolate
strains.
We
examined
their
sensitivity
6
therapeutic
monoclonal
antibodies
(mAbs)
72
sera
from
Pfizer
BNT162b2-vaccinated
individuals,
with
or
without
BA.1/BA.2
breakthrough
infection.
Ronapreve
(Casirivimab
Imdevimab)
Evusheld
(Cilgavimab
Tixagevimab)
lose
antiviral
efficacy
against
BA.2.75.2
BQ.1.1,
whereas
Xevudy
(Sotrovimab)
remaine
weakly
active.
is
also
resistant
Bebtelovimab.
Neutralizing
titers
triply
vaccinated
individuals
are
low
undetectable
4
months
after
boosting.
A
infection
increases
these
titers,
which
remains
about
18-fold
lower
than
BA.1.
Reciprocally,
more
efficiently
neutralization
BA.2.75.2.
Thus,
trajectory
novel
facilitates
spread
immunized
populations
raises
concerns
most
available
mAbs.
PLoS Pathogens,
Год журнала:
2022,
Номер
18(11), С. e1010951 - e1010951
Опубликована: Ноя. 18, 2022
SARS-CoV-2
continues
to
acquire
mutations
in
the
spike
receptor-binding
domain
(RBD)
that
impact
ACE2
receptor
binding,
folding
stability,
and
antibody
recognition.
Deep
mutational
scanning
prospectively
characterizes
impacts
of
on
these
biochemical
properties,
enabling
rapid
assessment
new
seen
during
viral
surveillance.
However,
effects
can
change
as
virus
evolves,
requiring
updated
deep
scans.
We
determined
all
single
amino
acid
Omicron
BA.1
BA.2
RBDs
ACE2-binding
affinity,
RBD
folding,
escape
from
binding
by
LY-CoV1404
(bebtelovimab)
monoclonal
antibody.
The
some
differ
those
measured
ancestral
Wuhan-Hu-1
background.
These
epistatic
shifts
largely
resemble
previously
Alpha
variant
due
convergent
epistatically
modifying
N501Y
substitution.
variants
show
additional
lineage-specific
shifts,
including
examples
phenomenon
entrenchment
causes
Q498R
substitutions
present
be
more
favorable
background
than
earlier
strains.
In
contrast,
substitution
Q493R
exhibits
no
sign
entrenchment,
with
derived
state,
R493,
being
unfavorable
for
Wuhan-Hu-1.
Likely
this
reason,
R493Q
reversion
has
occurred
sub-variants
BA.4/BA.5
BA.2.75,
where
affinity
buffer
may
potentiate
concurrent
antigenic
change.
Consistent
prior
studies,
we
find
have
reduced
expression,
identify
candidate
stabilizing
ameliorate
deficit.
Last,
our
maps
highlight
a
broadening
sites
compared
datasets
landscape
inform
ongoing
efforts
Nature,
Год журнала:
2023,
Номер
625(7993), С. 148 - 156
Опубликована: Ноя. 22, 2023
Abstract
The
continuing
emergence
of
SARS-CoV-2
variants
highlights
the
need
to
update
COVID-19
vaccine
compositions.
However,
immune
imprinting
induced
by
vaccination
based
on
ancestral
(hereafter
referred
as
WT)
strain
would
compromise
antibody
response
Omicron-based
boosters
1–5
.
Vaccination
strategies
counter
are
critically
needed.
Here
we
investigated
degree
and
dynamics
in
mouse
models
human
cohorts,
especially
focusing
role
repeated
Omicron
stimulation.
In
mice,
efficacy
single
boosting
is
heavily
limited
when
using
that
antigenically
distinct
from
WT—such
XBB
variant—and
this
concerning
situation
could
be
mitigated
a
second
booster.
Similarly,
humans,
infections
alleviate
WT
vaccination-induced
generate
broad
neutralization
responses
both
plasma
nasal
mucosa.
Notably,
deep
mutational
scanning-based
epitope
characterization
781
receptor-binding
domain
(RBD)-targeting
monoclonal
antibodies
isolated
infection
revealed
double
exposure
induce
large
proportion
matured
Omicron-specific
have
RBD
epitopes
WT-induced
antibodies.
Consequently,
was
largely
mitigated,
bias
towards
non-neutralizing
observed
exposures
restored.
On
basis
scanning
profiles,
identified
evolution
hotspots
XBB.1.5
demonstrated
these
mutations
further
boost
immune-evasion
capability
while
maintaining
high
ACE2-binding
affinity.
Our
findings
suggest
component
should
abandoned
updating
vaccines,
individuals
without
prior
receive
two
updated
boosters.
Cell Host & Microbe,
Год журнала:
2022,
Номер
30(11), С. 1540 - 1555.e15
Опубликована: Окт. 18, 2022
The
SARS-CoV-2
Omicron
BA.2.75
variant
emerged
in
May
2022.
is
a
BA.2
descendant
but
phylogenetically
distinct
from
BA.5,
the
currently
predominant
descendant.
Here,
we
show
that
has
greater
effective
reproduction
number
and
different
immunogenicity
profile
than
BA.5.
We
determined
sensitivity
of
to
vaccinee
convalescent
sera
as
well
panel
clinically
available
antiviral
drugs
antibodies.
Antiviral
largely
retained
potency,
antibody
varied
depending
on
several
key
BA.2.75-specific
substitutions.
spike
exhibited
profoundly
higher
affinity
for
its
human
receptor,
ACE2.
Additionally,
fusogenicity,
growth
efficiency
alveolar
epithelial
cells,
intrinsic
pathogenicity
hamsters
were
those
BA.2.
Our
multilevel
investigations
suggest
acquired
virological
properties
independent
potential
risk
global
health